RBC Capital analyst Luca Issi raised the firm’s price target on Ascendis Pharma (ASND) to $230 from $210 and keeps an Outperform rating on the shares. The company posted another strong beat for Yorvipath despite some FX headwinds while prescriber base also expanded from 1,000 to 1,750 docs, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma price target raised to $307 from $306 at UBS
- Ascendis Pharma price target raised to $290 from $243 at Citi
- Ascendis Pharma price target raised to $295 from $289 at Wells Fargo
- Ascendis Pharma’s Promising Growth Trajectory: Buy Rating Affirmed Amid Strong Yorvipath Performance and Strategic Pipeline Developments
- Ascendis Pharma Reports Strong Q2 2025 Growth